{"id":1002416,"date":"2026-09-10T08:51:57","date_gmt":"2026-09-10T12:51:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/"},"modified":"2026-09-10T08:51:57","modified_gmt":"2026-09-10T12:51:57","slug":"fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/","title":{"rendered":"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <b>New certificate program will prepare clinicians to support patients receiving COMP360 <span>psilocybin<\/span> treatment, if approved by the FDA<\/b>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\">NEW YORK<\/span>, <span class=\"legendSpanClass\">Sept. 10, 2026<\/span> \/PRNewswire\/ &#8212; Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its U.S. healthcare provider training grant program. Through the collaboration, Fluence is developing a new certificate program designed to prepare healthcare providers to deliver high-quality care for patients receiving COMP360\u00a0<span>psilocybin<\/span> treatment, if approved by the U.S. Food and Drug Administration (FDA).<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS1980975\/fluence_header_logo.jpg?id=OA2927665\" title=\"Fluence International, Inc.\" alt=\"Fluence International, Inc.\" \/>\n        <\/p>\n<\/p><\/div>\n<p>COMP360 is an investigational synthetic <span>psilocybin<\/span> treatment currently being evaluated for treatment-resistant depression. In anticipation of potential FDA approval and subsequent commercial availability, the <b>Post-Approval COMP360 <span>Psilocybin<\/span> Certificate Program<\/b>\u00a0will prepare clinicians with the knowledge and skills required to support patients throughout the COMP360 treatment experience. The program will combine Fluence&#8217;s experience training thousands of clinicians in psychedelic therapy with Compass Pathways&#8217; clinical guidance for COMP360.<\/p>\n<p>The certificate program will progress through three modules: <b>Foundations of Psychedelic Care, Understanding <span>Psilocybin<\/span>, and COMP360 Certification<\/b>. Clinicians will build foundational skills for supporting patients through psychedelic treatment, develop an understanding of <span>psilocybin<\/span> and the research behind its therapeutic use, and receive COMP360-specific training covering the compound, applicable regulations, patient preparation, treatment administration, and follow-up.<\/p>\n<p>&#8220;This is a moment Fluence has been preparing for since our earliest days,&#8221; said <b>Elizabeth Nielson, PhD, Chief Executive Officer and Co-Founder of Fluence<\/b>. &#8220;Our goal has always been to help clinicians translate rigorous psychedelic research into safe, skilled and evidence-based clinical practice. Working with Compass to prepare providers for the potential introduction of COMP360 allows us to bring together years of clinician education and clinical research training in a program designed for real-world care.&#8221;<\/p>\n<p>Fluence was a training partner selected by Compass Pathways through a competitive process based on expertise in psychedelic training design, delivery and governance, ability to scale, commitment to access and inclusion, and regulatory alignment.<\/p>\n<p>In addition to training individual clinicians, Fluence supports healthcare organizations preparing and managing clinical workforces at scale. Through its training operations platform, organizations can enroll providers and access real-time data on training progress, completion, competency and credentialing, providing the visibility and documentation needed to develop a consistently trained and verifiably prepared workforce.<\/p>\n<p>To <b>pre-enroll or learn more <\/b>visit our <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4766557-1&amp;h=1563907107&amp;u=https%3A%2F%2Fwww.fluencetraining.com%2Ftraining%2Fpost-approval-comp360-program&amp;a=website\" target=\"_blank\" rel=\"nofollow\">website<\/a>.<\/p>\n<p>\n        <b>About Fluence<\/b>\n      <\/p>\n<p>Fluence builds the human capabilities required for psychedelic and neuroplastogen care. Through evidence-based training, expert instruction, experiential practice and competency assessment, Fluence prepares clinicians to deliver high-quality care and enables organizations to develop competent, consistently trained and verifiably prepared providers. Fluence&#8217;s programs are grounded in clinical research and designed for the realities and responsibilities of clinical practice. <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4766557-1&amp;h=4187276432&amp;u=http%3A%2F%2Fwww.fluencetraining.com%2F&amp;a=www.fluencetraining.com\" target=\"_blank\" rel=\"nofollow\">www.fluencetraining.com<\/a>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=NY39993&amp;sd=2026-09-10\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training-302875218.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training-302875218.html<\/a><\/p>\n<p>SOURCE Fluence International, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY39993&amp;Transmission_Id=202609100800PR_NEWS_USPR_____NY39993&amp;DateId=20260910\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA NEW YORK, Sept. 10, 2026 \/PRNewswire\/ &#8212; Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its U.S. healthcare provider training grant program. Through the collaboration, Fluence is developing a new certificate program designed to prepare healthcare providers to deliver high-quality care for patients receiving COMP360\u00a0psilocybin treatment, if approved by the U.S. Food and Drug Administration (FDA). COMP360 is an investigational synthetic psilocybin treatment currently being evaluated for treatment-resistant depression. In anticipation of potential FDA approval and subsequent commercial availability, the Post-Approval &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1002416","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA NEW YORK, Sept. 10, 2026 \/PRNewswire\/ &#8212; Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its U.S. healthcare provider training grant program. Through the collaboration, Fluence is developing a new certificate program designed to prepare healthcare providers to deliver high-quality care for patients receiving COMP360\u00a0psilocybin treatment, if approved by the U.S. Food and Drug Administration (FDA). COMP360 is an investigational synthetic psilocybin treatment currently being evaluated for treatment-resistant depression. In anticipation of potential FDA approval and subsequent commercial availability, the Post-Approval &hellip; Continue reading &quot;Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-10T12:51:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1980975\/fluence_header_logo.jpg?id=OA2927665\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training\",\"datePublished\":\"2026-09-10T12:51:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\\\/\"},\"wordCount\":480,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1980975\\\/fluence_header_logo.jpg?id=OA2927665\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\\\/\",\"name\":\"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1980975\\\/fluence_header_logo.jpg?id=OA2927665\",\"datePublished\":\"2026-09-10T12:51:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1980975\\\/fluence_header_logo.jpg?id=OA2927665\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1980975\\\/fluence_header_logo.jpg?id=OA2927665\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/","og_locale":"en_US","og_type":"article","og_title":"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training - Market Newsdesk","og_description":"PR Newswire New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA NEW YORK, Sept. 10, 2026 \/PRNewswire\/ &#8212; Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its U.S. healthcare provider training grant program. Through the collaboration, Fluence is developing a new certificate program designed to prepare healthcare providers to deliver high-quality care for patients receiving COMP360\u00a0psilocybin treatment, if approved by the U.S. Food and Drug Administration (FDA). COMP360 is an investigational synthetic psilocybin treatment currently being evaluated for treatment-resistant depression. In anticipation of potential FDA approval and subsequent commercial availability, the Post-Approval &hellip; Continue reading \"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-10T12:51:57+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1980975\/fluence_header_logo.jpg?id=OA2927665","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training","datePublished":"2026-09-10T12:51:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/"},"wordCount":480,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1980975\/fluence_header_logo.jpg?id=OA2927665","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/","name":"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1980975\/fluence_header_logo.jpg?id=OA2927665","datePublished":"2026-09-10T12:51:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1980975\/fluence_header_logo.jpg?id=OA2927665","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1980975\/fluence_header_logo.jpg?id=OA2927665"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1002416"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002416\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1002416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1002416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1002416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}